$NVCT
Nuvectis Pharma, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024010971 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.540M $1.700M
YoY Change -7.78% 12.58%
% of Gross Profit
Research & Development $2.819M $2.943M
YoY Change -37.16% -30.95%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.819M $2.943M
YoY Change -37.16% -30.95%
Operating Profit -$4.359M -$4.643M
YoY Change -29.21% -19.56%
Interest Expense $206.0K $215.0K
YoY Change -26.43% 235.94%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.153M -$4.428M
YoY Change -29.37% -22.42%
Income Tax
% Of Pretax Income
Net Earnings -$4.153M -$4.428M
YoY Change -29.38% -22.42%
Net Earnings / Revenue
Basic Earnings Per Share -$0.24 -$0.26
Diluted Earnings Per Share -$0.24 -$0.26
COMMON SHARES
Basic Shares Outstanding 18.65M 18.36M
Diluted Shares Outstanding 17.23M 16.90M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.17M $18.12M
YoY Change -22.17% -26.36%
Cash & Equivalents $17.20M $18.10M
Short-Term Investments
Other Short-Term Assets $138.0K $182.0K
YoY Change -32.02% -46.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.31M $18.30M
YoY Change -22.26% -26.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $17.31M $18.30M
Total Long-Term Assets $0.00 $0.00
Total Assets $17.31M $18.30M
YoY Change -22.26% -26.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.261M $1.846M
YoY Change -35.25% 2.38%
Accrued Expenses $282.0K $310.0K
YoY Change 78.48% -45.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.316M $5.770M
YoY Change 13.27% 25.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.316M $5.770M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $6.316M $5.770M
YoY Change 13.27% 25.19%
SHAREHOLDERS EQUITY
Retained Earnings -$67.00M -$62.80M
YoY Change 40.76% 50.6%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.99M $12.53M
YoY Change
Total Liabilities & Shareholders Equity $17.31M $18.30M
YoY Change -22.26% -26.63%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$4.153M -$4.428M
YoY Change -29.38% -22.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.404M -$3.020M
YoY Change -25.8% -26.03%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.457M 1.672M
YoY Change 108.14% -87.35%
NET CHANGE
Cash From Operating Activities -2.404M -3.020M
Cash From Investing Activities
Cash From Financing Activities 1.457M 1.672M
Net Change In Cash -947.0K -1.348M
YoY Change -62.72% -114.76%
FREE CASH FLOW
Cash From Operating Activities -$2.404M -$3.020M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
dei Entity Central Index Key
EntityCentralIndexKey
0001875558
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41264
dei Entity Registrant Name
EntityRegistrantName
NUVECTIS PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2405608
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Bridge Plaza,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 275
dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Lee,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07024
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07024
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
614-3150
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
NVCT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18652688
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18116000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19126000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
182000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
59000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
18298000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19185000
CY2024Q2 us-gaap Assets
Assets
18298000
CY2023Q4 us-gaap Assets
Assets
19185000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1846000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2771000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
310000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
415000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3614000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3798000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5770000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6984000
CY2024Q2 us-gaap Liabilities
Liabilities
5770000
CY2023Q4 us-gaap Liabilities
Liabilities
6984000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18748751
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18748751
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17418886
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17418886
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
75372000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66446000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62844000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54245000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
12528000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12201000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18298000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19185000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2943000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4262000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5603000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6629000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1700000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1510000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3436000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3244000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4643000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5772000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9039000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9873000
CY2024Q2 nvct Finance Income
FinanceIncome
215000
CY2023Q2 nvct Finance Income
FinanceIncome
64000
nvct Finance Income
FinanceIncome
440000
nvct Finance Income
FinanceIncome
116000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4428000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5708000
us-gaap Net Income Loss
NetIncomeLoss
-8599000
us-gaap Net Income Loss
NetIncomeLoss
-9757000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4428000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5708000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8599000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9757000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16900570
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16900570
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15178035
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15178035
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16729952
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16729952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14951881
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14951881
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14219000
CY2023Q1 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1402000
CY2023Q1 nvct Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
663000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4049000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12274000
CY2023Q2 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
950000
CY2023Q2 nvct Offering Cost On Exercise Of Preferred Investment Options
OfferingCostOnExerciseOfPreferredInvestmentOptions
770000
CY2023Q2 nvct Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
816000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3110000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5708000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
20332000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12201000
CY2024Q1 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1296000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4696000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4171000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
14022000
CY2024Q2 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1262000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1672000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4428000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
12528000
us-gaap Profit Loss
ProfitLoss
-8599000
us-gaap Profit Loss
ProfitLoss
-9757000
us-gaap Share Based Compensation
ShareBasedCompensation
2558000
us-gaap Share Based Compensation
ShareBasedCompensation
2352000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
123000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-71000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-925000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1107000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-105000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
126000
nvct Increase Decrease In Accrued Compensation And Benefits
IncreaseDecreaseInAccruedCompensationAndBenefits
-184000
nvct Increase Decrease In Accrued Compensation And Benefits
IncreaseDecreaseInAccruedCompensationAndBenefits
-545000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7378000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8860000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6576000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3262000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
208000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
152000
nvct Payments Of Stock Issuance Costs Related To Initial Public Offering
PaymentsOfStockIssuanceCostsRelatedToInitialPublicOffering
341000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11178000
nvct Payments Of Issuance Costs For Warrant Exercise And Preferred Investment Option
PaymentsOfIssuanceCostsForWarrantExerciseAndPreferredInvestmentOption
371000
nvct Payments Of Stock Issuance Costs Related To Private Placement
PaymentsOfStockIssuanceCostsRelatedToPrivatePlacement
109000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6368000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13467000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1010000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4607000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19126000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19993000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18116000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24600000
nvct Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
399000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1 – GENERAL:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Nuvectis Pharma, Inc.  (hereafter – the “Company”) was incorporated under the laws of the State of Delaware on July 27, 2020 and commenced its principal operations in May 2021. The Company’s principal executive offices are located at Fort Lee New Jersey.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The Company is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In May 2021, the Company entered into a worldwide, exclusive license agreement with the CRT Pioneer Fund (“CRT”) (see Note 3a). In August 2021, the Company entered into a worldwide, exclusive license agreement with the University of Edinburgh, Scotland for the Company’s second drug candidate (see Note 3a).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In February 2022, the Company’s shares began trading on the NASDAQ under the symbol “NVCT”.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liquidity and Capital Resources</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The Company has incurred net operating losses since its inception and had an accumulated deficit of $62.8 million as of June 30, 2024. The Company had cash and cash equivalents of $18.1 million as of June 30, 2024 and has not generated positive cash flows from operations. To date, the Company has been able to fund its operations primarily through the issuance and sale of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">During the three months ended June 30, 2024, the Company sold a total of 246,691 common shares under its At-the-Market Program for aggregate total gross proceeds of approximately $1.7 million at an average selling price of $7.00 per share, resulting in net proceeds of approximately $1.7 million after deducting issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">During the six months ended June 30, 2024, the Company sold a total of 749,338 common shares under its At-the-Market Program for aggregate total gross proceeds of approximately $6.6 million at an average selling price of $8.78 per share, resulting in net proceeds of approximately $6.4 million after deducting issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">Management believes that its existing cash and cash equivalents as of June 30, 2024 enable the Company to fund planned operations for at least 12 months following the issuance date of these condensed financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;">The Company will need to raise additional capital in order to complete the clinical trials aimed at developing the product candidates until obtaining its regulatory and marketing approvals. There can be no assurances that the Company will be able to secure such additional financing, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force the Company to delay, limit, or reduce its products’ development, clinical trials, commercialization efforts or other operations, or even close down or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62800000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18100000
us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Use of Estimates in the Preparation of Financial Statements</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;">The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</p>
CY2024Q2 nvct Collaborative Agreement Amount Utilized From Fund Raising Commitment
CollaborativeAgreementAmountUtilizedFromFundRaisingCommitment
800000
CY2024Q2 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
0
CY2023Q4 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2023 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17418886
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17418886
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4428000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5708000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8599000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9757000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16900570
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15178035
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16729952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14951881
CY2024Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
18264047
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
18126323
CY2024Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1363477
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1396371
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16900570
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16729952
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-010971-index-headers.html Edgar Link pending
0001558370-24-010971-index.html Edgar Link pending
0001558370-24-010971.txt Edgar Link pending
0001558370-24-010971-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240630.xsd Edgar Link pending
tmb-20240630x10q.htm Edgar Link pending
tmb-20240630xex31d1.htm Edgar Link pending
tmb-20240630xex31d2.htm Edgar Link pending
tmb-20240630xex32d1.htm Edgar Link pending
tmb-20240630xex32d2.htm Edgar Link pending
tmb-20240630_cal.xml Edgar Link unprocessable
tmb-20240630_def.xml Edgar Link unprocessable
tmb-20240630_lab.xml Edgar Link unprocessable
tmb-20240630_pre.xml Edgar Link unprocessable
tmb-20240630x10q_htm.xml Edgar Link completed